CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
Germany's BGR Assesses NextSource Materials' Molo Graphite Mine as Part of Federal Critical Minerals Study
